单细胞分析揭示MDM2抑制后TP53突变克隆的选择
本研究探讨MDM2抑制对慢性骨髓增殖性肿瘤(MPN)中TP53突变细胞的选择作用。采用DNA单细胞方法分析克隆结构,发现TP53突变是MPN的晚期事件,主要发生在驱动克隆中,克隆演化常表现为序贯分支而非线性连续获得突变。MDM2抑制剂治疗可在体外直接促进TP53突变亚克隆的出现。
要点
- TP53突变是MPN向白血病转化的晚期事件,主要发生在驱动克隆中。
- 克隆演化常表现为序贯分支,而非同一克隆内线性连续获得突变。
- MDM2抑制剂治疗可在体外直接促进TP53突变亚克隆的出现。
核心结论
- MDM2抑制可直接促进MPN中TP53突变亚克隆的出现。
- TP53突变是MPN的晚期事件,主要发生在驱动克隆中。
- 克隆演化常为序贯分支而非线性连续获得突变。
研究设计与样本
- 采用DNA单细胞方法分析MPN患者细胞的克隆结构。
- 体外实验评估MDM2抑制对TP53突变细胞的选择作用。
主要发现
- TP53突变是MPN的晚期事件,主要发生在驱动克隆中。
- 克隆演化常表现为序贯分支而非线性连续获得突变。
- 在单细胞水平,额外突变的存在不影响MDM2抑制剂对TP53突变细胞的选择。
- 描述了一种可预测TP53突变克隆出现的体外试验。
临床怎么用
- 作者描述了一种体外试验,可预测TP53突变克隆的出现。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The mechanisms of transformation of chronic myeloproliferative neoplasms (MPN) to leukemia are largely unknown, but TP53 mutations acquisition is considered a key event in this process. p53 is a main tumor suppressor, but mutations in this protein per se do not confer a proliferative advantage to the cells, and a selection process is needed for the expansion of mutant clones. MDM2 inhibitors may rescue normal p53 from degradation and have been evaluated in a variety of cancers with promising results. However, the impact of these drugs on TP53-mutated cells is underexplored. We report herein evidence of a direct effect of MDM2 inhibition on the selection of MPN patients' cells harboring TP53 mutations. To decipher whether these mutations can arise in a specific molecular context, we used a DNA single-cell approach to determine the clonal architecture of TP53-mutated cells. We observed that TP53 mutations are late events in MPN, mainly occurring in the driver clone, whereas clonal evolution frequently consists of sequential branching instead of linear consecutive acquisition of mutations in the same clone. At the single-cell level, the presence of additional mutations does not influence the selection of TP53 mutant cells by MDM2 inhibitor treatment. Also, we describe an in vitro test allowing to predict the emergence of TP53 mutated clones. Altogether, this is the first demonstration that a drug treatment can directly favor the emergence of TP53-mutated subclones in MPN.
引用
- Maslah N, Verger E, Giraudier S, et al. Single-cell analysis reveals selection of TP53-mutated clones after MDM2 inhibition. Blood Adv. 2022. PMID: 35030630. doi:10.1182/bloodadvances.2021005867
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。